Ad Panel Finds Compounded Tirzepatide Claims Unsupported
Adults weighing compounded tirzepatide weight-loss products should know regulators found the advertised health benefits lacked adequate evidence.
Updated on Nov. 4, 2026 in Diabetes
Live Poll
Would you trust a telehealth ad for compounded weight-loss drugs over your doctor's advice?
The National Advertising Division, an advertising self-regulatory body run by BBB National Programs, recommended that Good Life Meds stop making certain health benefit and personalization claims for its compounded Tirzepatide+ products after a challenge from Eli Lilly. Good Life Meds voluntarily and permanently discontinued some of the challenged claims during the inquiry, and the recommendation was announced November 4, 2026.
Why it matters
The ruling addresses marketing of compounded tirzepatide, a drug class that Eli Lilly's approved products Mounjaro and Zepbound represent, to patients who may be considering telehealth weight-loss options. Regulators found the company lacked a reasonable basis for its claimed health benefits, which matters for consumers judging whether these products have been shown to be safe and effective.
The National Advertising Division reviewed substantiation Good Life submitted, including clinical literature on tirzepatide, literature on additive ingredients, a Gallup survey, and retrospective cohort studies. NAD found this evidence did not fit the challenged claims, because the tirzepatide literature largely concerned Lilly's FDA-approved products.
The players
Eli Lilly and Company
Eli Lilly is a pharmaceutical company that makes Mounjaro and Zepbound, the FDA-approved tirzepatide medications for type 2 diabetes and chronic weight management.
Good Life Meds
Good Life Meds is a telehealth platform that markets prescription weight-loss medications, including compounded tirzepatide sold as Tirzepatide+.
BBB National Programs' National Advertising Division
The National Advertising Division is the advertising self-regulatory body that reviewed the challenge and issued the recommendation.
The details
Tirzepatide is an approved medicine for type 2 diabetes and chronic weight management when made by the manufacturer under FDA approval. Compounded versions are prepared by pharmacies rather than the manufacturer, and Good Life marketed its version as Tirzepatide+ with added ingredients. NAD concluded that the supporting studies did not test that combination, and that the personalization claims overstated how individualized the products are.
Timeline
November 4, 2026: NAD recommendation announced and press release issued.
Health Landscape
Compounded tirzepatide has been sold widely while Mounjaro and Zepbound are FDA-approved for type 2 diabetes and chronic weight management. This ruling shows that advertising claims for compounded versions are being scrutinized against the evidence available for the approved products.
If you are considering a compounded tirzepatide product, it is worth asking your physician whether the evidence for that specific product applies to you. Ask your prescriber about the safety and efficacy of approved tirzepatide options before deciding.
The takeaway
Marketing claims for compounded medications can outrun the evidence behind them, so checking whether a product's studies actually tested that product is a useful step. Discuss any weight-loss medication with your physician, including whether an FDA-approved option is appropriate for you.
Further reading
For broader context on the medication class at the center of this ruling, see Diabetes coverage.
Live Poll
Would you trust a telehealth ad for compounded weight-loss drugs over your doctor's advice?
